

NATIONAL COMMUNICABLE DISEASE CENTER

# **BIOLOGICS**

SURVEILLANCE



National Communicable Disease Center

Report No. 42

July, August, September, 1969

### BIOLOGICS SURVEILLANCE REPORT

This summary is intended primarily for those concerned with the national use and application of immunizing agents. Although the "Net Distribution" figures are recognized as representing rough approximations only, we believe that a continuing analysis of this kind, interpreted in the light of national and local immunization surveys, will aid in assessing the overall immunization status of the population. It is anticipated that a knowledge of utilization and inventory data will assist in foreseeing possible critical shortages in vaccine supply.

To maintain confidentiality of an individual commercial manufacturer's report for economic and production reasons, current tabulations are available only when at least three producers market and report figures for essentially the same product. This is a basic agreement of the Biologics Surveillance Program.

In some instances, where adequate time has elapsed since production and distribution, manufacturers have allowed the data to be released when not all the criteria of confidentiality could be met. Addition of these data to the summaries completes the "natural history" of early patterns of vaccine utilization.

Each major antigen is represented in the form of a line graph showing "Estimated Net Distribution" for the previous year and through the above month in 1969. Estimated Net Distribution represents doses of each vaccine distributed for use during the reporting period and is depicted as gross sales or distribution less recordable returned doses. In addition, specific data is tabulated for each antigen reported during the third quarter in 1969. Civilian and military data have been combined.

COOPERATING IN THIS PROGRAM ARE THE FOLLOWING:

Charles Pfizer & Co., Inc.	Parke, Davis & Company
Courtland Laboratories	The Philadelphia Blood Center
Cutter Laboratories	Philips Roxane, Inc.
Eli Lilly and Company	Pitman-Moore Company
E. R. Squibb & Sons	Wyeth Laboratories
Hyland Laboratories	Illinois Department of Public Health
Lederle Laboratories	Massachusetts Department of Public Health
Merck Sharp & Dohme	Michigan Department of Health
The National Drug Company	Texas State Department of Health

National Communicable Disease Center	David J. Sencer, M.D., Director
Advisory Committee on Immunization Practices	H. Bruce Dull, M.D. Secretary, A.C.I.P.; Assistant Director, NCDC
Biologics Surveillance	Morris T. Suggs, D.P.H. Acting Chief Immunobiologics Activity Laboratory Division

MONTHLY BIOLOGIC SUMMARY FOR JULY 1969

LINE NO.	PRODUCT DESCRIPTION	A* GROSS NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	D NO. OF DOSES RETURNED DURING MONTH	E* NET NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	B* NO. OF FINISHED DOSES READY FOR IMMEDIATE SHIPMENT AT MONTH END	C NO. OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIPMENT
1-	Influenza Virus Vaccine (if applicable, specify type) Monovalent	1,660	10,800	- 9,140	57,360	**
	Bivalent	1,859,830	63,245	1,796,585	2,165,600	**
	Polyvalent	**	**	**	**	**
2.	Diphtheria Toxoid with Tetanus Toxoid (Pediatric)	271,092	46,750	224,342	1,074,784	615,577
3.	Diphtheria and Tetanus Toxoids with Pertussis Vaccine	2,444,630	185,808	2,258,822	1,426,077	778,724
4.	Tetanus Toxoid with Diphtheria Toxoid (Adult)	395,900	11,800	384,100	1,157,120	656,410
5.	Diphtheria Toxoid	420	2,420	- 2,000	5,110	**
6.	Tetanus Toxoid	2,761,226	167,734	2,593,492	8,512,025	1,273,573
7.	Pertussis Vaccine	10,205	1,365	8,840	56,220	**
8.	Diphtheria-Tetanus Toxoids and Poliomyelitis Vaccine Combined: Diphtheria-Tetanus Toxoids and Pertussis and Poliomyelitis Vaccines Combined	**	**	**	**	**
9.	Poliomyelitis Vaccine (Inactivated)	**	**	**	**	**
10.	Poliomyelitis Vaccine, Live, Oral, Type 1	84,322	24,807	59,515	115,793	**
	Type 2	44,081	2,995	41,086	205,252	**
	Type 3	30,725	780	29,945	135,275	**
11.	Poliomyelitis Vaccine, Live, Oral, Trivalent	1,521,755	5,360	1,516,395	4,337,760	**
12.	Measles Virus Vaccine, Live, Attenuated	465,253	113,036	352,217	713,919	**
13.	Smallpox Vaccine	1,254,084	45,834	1,208,250	2,948,949	20,437,482
14.	Rabies Vaccine	48,148	686	47,462	60,554	153,416
15.	Immune Serum Globulin (Human)	424,620 cc	46,882 cc	377,738 cc	1,423,748 cc	732,520 cc
	Measles Immune Globulin (Human)	** cc	** cc	** cc	** cc	** cc
	Poliomyelitis Immune Globulin (Human)	** cc	** cc	** cc	** cc	** cc
	Tetanus Immune Globulin (Human)	66,561 cc	505 cc	66,056 cc	132,855 cc	** cc
16.						
17.						

\*COLUMN E IS COLUMN A LESS COLUMN D OR NET DOSES DISTRIBUTED; COLUMNS A AND B INCLUDE DOMESTIC AND MILITARY.

\*\*NOT SHOWN SINCE LESS THAN THREE PRODUCERS REPORTED.



MONTHLY BIOLOGIC SUMMARY FOR SEPTEMBER 1969

LINE NO.	PRODUCT DESCRIPTION	A* GROSS NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	D NO. OF DOSES RETURNED DURING MONTH	E* NET NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	B* NO. OF FINISHED DOSES READY FOR IMMEDIATE SHIPMENT AT MONTH END	C NO. OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIPMENT
1-	Influenza Virus Vaccine (if applicable, specify type) Monovalent	2,500	7,030	- 4,530	**	**
	Bivalent	7,264,135	135,800	7,128,335	2,008,900	**
	Polyvalent	**	**	**	**	**
2.	Diphtheria Toxoid with Tetanus Toxoid (Pediatric)	255,020	21,690	233,330	963,978	498,187
3.	Diphtheria and Tetanus Toxoids with Pertussis Vaccine	2,131,082	95,503	2,035,579	1,509,240	405,823
4.	Tetanus Toxoid with Diphtheria Toxoid (Adult)	1,003,990	10,060	993,930	1,351,660	768,322
5.	Diphtheria Toxoid	580	700	- 120	4,690	**
6.	Tetanus Toxoid	2,069,619	93,359	1,976,260	4,584,233	2,021,600
7.	Pertussis Vaccine	17,425	645	16,780	29,825	**
8.	Diphtheria-Tetanus Toxoids and Poliomyelitis Vaccine Combined: Diphtheria-Tetanus Toxoids and Pertussis and Poliomyelitis Vaccines Combined	**	**	**	**	**
9.	Poliomyelitis Vaccine (Inactivated)	**	**	**	**	**
10.	Poliomyelitis Vaccine, Live, Oral, Type 1	33,837	11,626	22,211	164,904	**
	Type 2	42,008	1,593	40,415	202,857	**
	Type 3	26,050	385	25,665	175,320	**
11.	Poliomyelitis Vaccine, Live, Oral, Trivalent	1,669,715	11,260	1,658,455	5,218,940	**
12.	Measles Virus Vaccine, Live, Attenuated	440,362	30,416	409,946	398,348	**
13.	Smallpox Vaccine	1,502,002	85,064	1,416,938	2,577,289	22,870,943
14.	Rabies Vaccine	25,305	203	25,102	84,076	110,670
15.	Immune Serum Globulin (Human)	565,584 cc	22,705 cc	542,879 cc	954,776 cc	505,750 cc
	Measles Immune Globulin (Human)	** cc	** cc	** cc	** cc	** cc
	Poliomyelitis Immune Globulin (Human)	** cc	** cc	** cc	** cc	** cc
	Tetanus Immune Globulin (Human)	64,689 cc	968 cc	63,721 cc	160,942 cc	** cc
16.						
17.						

\*COLUMN E IS COLUMN A LESS COLUMN D OR NET DOSES DISTRIBUTED; COLUMNS A AND B INCLUDE DOMESTIC AND MILITARY.

\*\*NOT SHOWN SINCE LESS THAN THREE PRODUCERS REPORTED.

BIOLOGICS – UNITED STATES, 1969

Biologics	Net Total Doses
	July through September 1969
Influenza Virus Vaccine (Monovalent)	– 22,520
Influenza Virus Vaccine (Polyvalent)	**
Influenza Virus Vaccine (Bivalent)	14,485,890
Diphtheria Toxoid	– 2,160
Pertussis Vaccine	31,665
Tetanus Toxoid	7,464,542
Poliomyelitis Vaccine*	**
Poliovirus Vaccine, Live, Oral, Type 1	100,189
Poliovirus Vaccine, Live, Oral, Type 2	123,284
Poliovirus Vaccine, Live, Oral, Type 3	87,215
Poliovirus Vaccine, Live, Oral, Trivalent	5,438,655
Measles Virus Vaccine, Live, Attenuated	1,132,554
Smallpox Vaccine	4,831,523
Rabies Vaccine	118,697
Immune Serum Globulin (Human)	1,323,839
Poliomyelitis Immune Globulin (Human)	**
Tetanus Immune Globulin (Human)	189,789

\*Inactivated (Salk Type)


COMBINED BIOLOGICS – UNITED STATES, 1969

Biologics	Net Total Doses
	July through September 1969
Diphtheria and Tetanus Toxoids Combined	777,778
Diphtheria and Tetanus Toxoids and Pertussis Vaccine Combined	5,559,756
Tetanus and Diphtheria Toxoids Combined (For Adult Use)	2,190,680
Diphtheria and Tetanus Toxoids and Poliomyelitis Vaccine; Diphtheria and Tetanus Toxoids and Pertussis and Poliomyelitis Vaccines	**

\*\*Not shown since fewer than three producers reported.

Figure 1.

DIPHTHERIA AND TETANUS TOXOIDS, PERTUSSIS VACCINE  
UNITED STATES\* (Net Distribution by Month)



\*INCLUDES ALL PRODUCTS CONTAINING THESE ANTIGENS





Figure 3.

MEASLES VIRUS VACCINE, LIVE ATTENUATED  
UNITED STATES  
(Net Distribution by Month)






Figure 4.

SMALLPOX VACCINE - UNITED STATES  
(Net Distribution by Month)




*Figure 5.*

**INFLUENZA VIRUS VACCINE · UNITED STATES\***  
(Net Distribution by Month)



\* INCLUDES ALL PRODUCTS CONTAINING INFLUENZA VACCINE

**Figure 6.**  
**RABIES VACCINE · UNITED STATES**  
 (Net Distribution by Month)



**Figure 7.**

**IMMUNE SERUM GLOBULINS (HUMAN)**  
**UNITED STATES**  
 (Net Distribution by Month)

